Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …

This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …